Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PFC + CQ is a combination drug consisting of two active pharmaceutical ingredients, most likely referring to perfluorocarbon (PFC) and chloroquine (CQ). Perfluorocarbons are synthetic compounds known for their high capacity to dissolve gases such as oxygen and carbon dioxide, and have been investigated as artificial blood substitutes or oxygen carriers. Chloroquine is a well-known antimalarial agent that also exhibits immunomodulatory effects and has been studied for various infectious diseases. The combination of PFC with chloroquine has been explored in preclinical research settings, particularly in the context of enhancing drug delivery or improving tissue oxygenation during hypoxic conditions. However, there is no evidence from the provided sources that "PFC + CQ" is an approved pharmaceutical product or marketed under this name.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PFC + CQ.